- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
SOHO Annual Meeting | Conferences
Research Shows Promise for Directing Later Lines of Therapy for Hodgkin Lymphoma
October 02, 2022
Research now is addressing how subsequent therapies can meet needs of patients with Hodgkin lymphoma who progress after early lines of treatment.
Relapse Less Likely With Orca-T vs Standard Transplant in Hematologic Malignancies
October 01, 2022
In comparison with conventional transplant options, Orca-T may be more effective with a lower probability of infection in patients with hematologic malignancies.
Bispecifics vs CAR T-Cell Therapy: Which Is Better in Relapsed/Refractory Multiple Myeloma?
October 01, 2022
Chimeric antigen receptor T-cell therapy is one such newer class of therapy to be introduced into the treatment paradigm for multiple myeloma, and bispecific antibodies are the expected next class of treatments to emerge in the clinic.
Polatuzumab Vedotin Plus Rituximab Bests R-CHOP in Treatment-Naïve DLBCL
September 30, 2022
Results from the POLARIX clinical trial support the use of polatuzumab vedotin plus rituximab as frontline treatment for diffuse large B-cell lymphoma.
Precise Selection of Treatment for Follicular Lymphoma
September 30, 2022
When choosing a treatment regimen for follicular lymphoma, an individualized approach is necessary, according to Loretta J. Nastoupil, MD.
Future Directions for MPN Research
September 30, 2022
Srdan Verstovsek, MD, PhD, highlights what future research in myeloproliferative neoplasms looks to examine.
Immune Checkpoint Inhibitors and Novel Agents Are Explored in Hodgkin Lymphoma
September 30, 2022
As the brentuximab vedotin plus AVD combination gains widespread use, clinicians should recognize the toxicities, such as the risk of neutropenic fever or peripheral neuropathy, according to Alison Moskowitz, MD.
Emerging EZH 1/2 Inhibitors Demonstrate Single-Agent Efficacy in R/R PTCL
September 30, 2022
Novel targets continue to emerge through clinical trials in peripheral T0cell lymphoma, in particular EZH 1 and EZH 2 inhibitors, which have strong single-agent efficacy.
Potential of Menin Inhibitors Is Focus of AML Session
September 30, 2022
AUGMENT-101 demonstrates the potential of menin inhibitors for the treatment of patients with acute myeloid leukemia.